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Quantifying Transmission of
Clostridium difficile within and
outside Healthcare Settings
David P. Durham, Margaret A. Olsen, Erik R. Dubberke, Alison P. Galvani, Jeffrey P. Townsend

To quantify the effect of hospital and community-based
transmission and control measures on Clostridium difficile
infection (CDI), we constructed a transmission model within
and between hospital, community, and long-term care-facility settings. By parameterizing the model from national
databases and calibrating it to C. difficile prevalence and
CDI incidence, we found that hospitalized patients with CDI
transmit C. difficile at a rate 15 (95% CI 7.2–32) times that
of asymptomatic patients. Long-term care facility residents
transmit at a rate of 27% (95% CI 13%–51%) that of hospitalized patients, and persons in the community at a rate of
0.1% (95% CI 0.062%–0.2%) that of hospitalized patients.
Despite lower transmission rates for asymptomatic carriers
and community sources, these transmission routes have
a substantial effect on hospital-onset CDI because of the
larger reservoir of hospitalized carriers and persons in the
community. Asymptomatic carriers and community sources
should be accounted for when designing and evaluating
control interventions.

I

nfection with the nosocomial pathogen Clostridium difficile is a major risk in healthcare settings and long-term
care facilities (LTCFs) and has an increasing prevalence in
the broader community. Infection is diagnosed in >250,000
hospitalized persons annually in the United States (1). Colonization of the gut microbiota with C. difficile can be innocuous and asymptomatic. However, antimicrobial drugs
disrupt the normal intestinal microbial architecture and can
enable proliferation of C. difficile (2). An insufficient host
antibody response to C. difficile toxins A and B can then
lead to C. difficile infection (CDI). CDI is a severe diarrheal disease that is concentrated among elderly persons and
those with extended hospital stays or residing in LTCFs.
The relative risk for CDI, given recent antimicrobial drug
exposure, differs greatly among antimicrobial drug classes
and ranges from no relative risk when receiving tetracyclines to a 20-fold relative risk when receiving clindamycin
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(2). Despite an increasing interest in C. difficile biology and
the epidemiology of CDI, fundamental questions about reservoirs and routes of transmission remain unanswered.
Molecular typing and contact tracing studies have estimated that 10%–38% of CDI cases that occur >48 hours after hospital admission (termed hospital-onset CDI) can be
attributed to transmission from known symptomatic contacts within the hospital (3–6). These estimates suggest that
a substantial proportion of CDI arises from other sources,
such as transmission from patients with asymptomatic colonization or community acquisition (3,5,7,8). The relative
role of these routes of transmission to the epidemiology of
C. difficile is crucial for determining effectiveness of hospital-based measures to control infection. In addition, toxin-targeting treatments, such as vaccines, nontoxigenic C.
difficile, and monoclonal antibodies, might protect against
CDI but are unlikely to prevent asymptomatic colonization
with C. difficile (9). To predict the effectiveness of these
emerging therapies, it is critical to understand the role of
asymptomatic carriers in CDI epidemiology.
Mathematical models of C. difficile colonization have
generated insights regarding the epidemiologic role of
antimicrobial drugs on CDI outbreaks (10). Such models
have also quantified the effect of hospital-based control interventions (11–14) and demonstrated the crucial roles of
asymptomatic colonization and patients with exposure before hospital admission in sustaining hospital transmission
(7,13). Most studies have focused on the hospital setting.
To fully understand the epidemiology of the pathogen and
to inform decisions regarding control strategies, it is crucial
to quantify the relative transmission of C. difficile in the
hospital and in the broader community (8).
To evaluate the relative role of asymptomatic hospital transmission, symptomatic hospital transmission,
LTCF transmission, and community transmission, we integrated diverse clinical and epidemiologic data into a dynamic model of C. difficile transmission within and among
hospitals, LTCFs, and community settings in the United
States. We parameterized our model by using Medicare
and Healthcare Cost and Utilization Project databases and
data from published epidemiologic and clinical research.
To estimate infectivity of symptomatic and asymptomatic
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patients in the hospital; corresponding infectivity of persons in LTCFs and in the community; and average risks for
acquiring C. difficile in the hospital, LTCF, and the community, we fit our model to estimated toxigenic C. difficile
colonization and CDI incidence in each of these settings.
Furthermore, we calculated the effect on CDI incidence of
targeting key aspects of CDI epidemiology with control interventions in each of the 3 settings.
Methods
Definitions

We refer to acquisition of C. difficile from human sources
as C. difficile transmission and acquisition of C. difficile
from nonhuman sources as nonhuman acquisition. Asymptomatic persons carrying C. difficile are referred to as colonized. Persons carrying C. difficile and symptomatic for
diarrheal disease associated with C. difficile are referred to
as persons with CDI.
Model Structure

Previous models have focused almost exclusively on the
hospital setting (7,8,10,12). We constructed a new model
that encompasses C. difficile transmission and symptomatic CDI within a hospital, an LTCF, and an associated midsized community and quantifies patient movement between
these settings. We parameterized our model with data from
a combination of sources, including published literature,
the US Census, national hospital and LTCF surveys, and
the Healthcare Cost and Utilization Project and Medicare
databases (online Technical Appendix, http://wwwnc.cdc.
gov/EID/article/22/4/15-0455-Techapp1.pdf).
We structured our model in compartments (Figure 1)
composed of patients who are currently receiving antimicrobial drugs, those who have a history of antimicrobial
drug use and an increased risk for CDI, or those who do
not have a recent history of receiving antimicrobial drugs.
Consistent with clinical observations (15), we assumed that
the increased risk for CDI after antimicrobial drug use reverted to normal in an average of 45 days. Uncolonized
patients could become asymptomatically colonized with
C. difficile because of transmission from asymptomatic
patients, transmission from patients with CDI, or through
acquisition from background sources in the community.
Asymptomatically colonized patients could remain asymptomatic, spontaneously clear their colonization, or develop
symptomatic CDI. Patients with CDI could recover and be
at temporarily increased risk for recolonization, could recover and remain colonized and at risk for recurrence, or
could die from the disease. We included 3 CDI and recurrence classes, each with a successively higher likelihood of
recurrence, to reflect clinical observations of the increasing likelihood of recurrence after multiple CDI episodes

Figure 1. Compartmental model structure for Clostridium difficile
infection (CDI) within each setting (hospital, long-term care
facility, and community). Patients are classified as not receiving
antimicrobial drugs (N), are receiving antimicrobial drugs (A),
having a recent history of receiving antimicrobial drugs (O),
uncolonized (U), asymptomatically colonized (C), symptomatically
infected (CDI), or colonized and subject to recurrence (RC) of
CDI. Arrows indicate changes in individual epidemiologic status.
Subscripts indicate primary, secondary, or tertiary CDI.

(16–18). We assumed that all patients with CDI were first
asymptomatically colonized before symptoms developed.
We embedded this epidemiologic model within a model
of patient flow between the hospital, LTCF, and community
(Figure 2), parameterized from national hospital and longterm-care-facility survey data. Patients with CDI remained
hospitalized for an additional 3.1 days (95% CI 2.3–4.0 days)
(19–21). Patients with CDI had a 96% (95% CI 93%–99%)
probability of being given a diagnosis and subjected to isolation protocols that reduced transmission by 53% (95% CI
37%–72%) (22–25). We further assumed that persons in the
community and in an LTCF in whom CDI developed were
hospitalized with probabilities of 26% (95% CI 23%–28%)
and 27% (95% CI 23%–32%), respectively (Table 1) (26,27).
Demographics

To represent demographically stratified CDI risk between
the 3 settings, we modeled 5 demographic groups: persons
<50 years of age, those 50–65 years of age without concurrent conditions, those 50–65 years of age with concurrent
conditions, those >65 years of age without concurrent conditions, and those >65 years of age with concurrent conditions. Therefore, our full model consisted of base epidemiology (Figure 1) applied to each of the 5 demographic
groups, and each group populated and moved between the
hospital, LTCF, and the community (Figure 2) at rates calibrated from published C. difficile literature, US hospital
discharge and census data, and Medicare and Healthcare
Cost and Utilization Project databases (online Technical
Appendix Table 4). We assumed that colonized patients
with concurrent conditions are at greater risk for development of CDI (online Technical Appendix).
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Figure 2. Transitions between settings (hospital, LTCF, and the non–healthcare community) for model structure of Clostridium difficile
infection (CDI). Transitions were parameterized at demographically calibrated, age-specific rates. Hospitalized patients with CDI
who were given a diagnosis are subject to enhanced isolation protocols that reduce transmission. All hospitalized CDI patients are
discharged at a slower rate than non–CDI patients, which reflects longer hospitalization attributable to CDI. N, patients not receiving
antimicrobial drugs; A, patients receiving antimicrobial drugs; O, patients with a recent history of receiving antimicrobial drugs; U,
uncolonized patients; C, asymptomatically colonized patients; RC, symptomatically infected patients or colonized patients and subject
to recurrence; LTCF, long-term care facility. Solid arrows indicate changes in individual epidemiologic status and patient movement
between the hospital, community, and LTCF. Dashed arrows indicate isolation of CDI patients.

Transmission

We specified 5 C. difficile transmission rates: 1) the base
CDI rate at which patients without a diagnosis and symptomatic CDI transmit in the hospital, 2) the base asymptomatic rate at which asymptomatically colonized patients
transmit in the hospital, 3) the LTCF transmission rate representing the relative infectivity of persons in LTCFs compared with patients in the hospital, 4) the community transmission rate representing the relative infectivity of persons
in the community compared with patients in the hospital,
and 5) the rate of C. difficile acquisition from nonhuman
reservoirs. We further defined the force of colonization as
the rate at which uncolonized patients become asymptomatically colonized with C. difficile and specified 3 separate
force-of-colonization rates: 1) the hospital, 2) LTCF, and
3) the community.
For the force of colonization in the hospital, we
specified that nonisolated symptomatic patients with CDI
transmit at the base CDI rate, that isolated patients with
CDI transmit at the base CDI rate multiplied by the probability that isolation measures are insufficient, and that
610

asymptomatically colonized patients transmit at the base
asymptomatic rate. We assumed direct contact mixing
and density-dependent transmission, which is consistent
with the observation that larger hospitals have greater
CDI incidence than smaller hospitals (36). Environmental
contamination and transmission mediated by healthcare
workers were implicitly included by our calibration of
the base CDI rate and the base asymptomatic rate. Hospital hygiene was separated into 2 components: overall
hospital hygiene, which influenced transmission from asymptomatically colonized patients and from undiagnosed
patients with CDI; and the probability of, and effectiveness of, enhanced isolation protocols for patients given a
diagnosis of CDI.
For the force of colonization in the LTCF, we made 3
assumptions. First, enhanced isolation protocols were not
available. Second, patients with CDI transmit at the base
CDI rate multiplied by the LTCF transmission rate modifier. Third, asymptomatically colonized patients transmit at
the base asymptomatic rate multiplied by the LTCF transmission rate modifier.
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Table 1. Epidemiologic and clinical model parameters for infection with Clostridium difficile*
Parameter description
Prior rate (95% CI)†
Epidemiology
All-cause CDI mortality rate, %
Age, y
<50
4.7 (2.6–7.6)
50–64
12 (8.7–16)
>65
16.6 (14–19)
Rate at which patients complete antimicrobial drug
0.22 (0.17–2.29)
course
Rate at which recurrence develops in recovered
0.13 (0.24–1)
patients
Rate at which patients not receiving antimicrobial drugs
0.038 (0.012–0.062)
at increased risk for CDI revert to normal risk
Rate of recovery from CDI
0.099 (0.090–0.11)
Probability that a patient recovering from primary CDI
22 (13–34)
will have >1 recurrence
Probability that a patient recovering from a first
33 (19–48)
recurrence will have a second recurrence
Probability that a patient recovering from multiple
56 (42–70)
recurrences will have an additional recurrence
Relative risk for CDI developing while a patient receives
8.9 (4.9–13.)
antimicrobial drugs
Relative risk for CDI among persons 50–65 y of age vs.
2.2 (1.4–3.4)
those <50 y of age
Relative risk for CDI among persons >65 y of age
2.9 (1.9–4.4)
compared with those <50 y of age
Spontaneous clearance of asymptomatic C. difficile
0.020 (0.015–0.025)
colonization
Hospital protocols
All-cause fraction of community-onset CDI in patients
0.26 (0.23–0.28)
who are hospitalized
All-cause fraction of LTCF-onset CDI in patients who
0.27 (0.23–0.32)
are hospitalized
Increased attributable length of stay for hospitalized
3.1 (2.3–4.0)
patients with CDI
Effectiveness of enhanced infection control measures in
53 (37–72)
reducing transmission
Probability that a patient with CDI is properly identified
0.96 (0.93–0.99)‡
and given enhanced infection control measures
Antimicrobial drug use rates
Prescription rate among persons in community
Age, y
<50
0.0013 (0.00095–0.0017)
50–64
0.0014 (0.00097–0.0018)
>65
0.0017 (0.0013–0.0021)
Prescription rate among patients in hospital
0.37 (0.22–0.66)
Prescription rate among patients in LTCF
0.0054 (0.0027–0.009)

Posterior rate (95% CI)†

Reference
(28)

4.5 (2.6–7.5)
12 (8.5–16)
17 (14–19)
0.22 (0.17–2.29)

(29)

0.2 (0.32–1.05)

(30)

0.033 (0.014–0.056)

(15)

0.099 (0.092–0.11)
24 (15–36)

(22)
(16,17)

34 (20–48)

(16,17)

56 (41–68)

(17,18)

8.3 (4.2–12)

(2,15)

2.2 (1.5–3.0)

(31)

3.2 (2.1–4.3)

(31)

0.021 (0.016–0.026)

(32)

0.26 (0.23–0.28)

(26)

0.27 (0.23–0.32)

(27)

3.1 (2.3–4.1)

(19–21)

52 (37–68)

(22,23)

0.96 (0.94–0.99)

(24,25)
(33,34)

0.0014 (0.00095–0.0018)
0.0014 (0.00097–0.0017)
0.0017 (0.0013–0.0022)
0.37 (0.21–0.68)
0.0052 (0.0026–0.0087)

*CDI, C. difficile infection; LTCF, long-term care facility.
†Parameter rates are per day unless otherwise indicated.
‡A total of 73% of sites initiated protocols before laboratory confirmation and 27% initiated protocols after confirmation. Sensitivity was 86% for
laboratory tests, which yielded an effective diagnosis rate of 0.73 + 0.27 × 0.86 = 0.96.

For the force of colonization in the community, we
assumed that C. difficile could be acquired from nonhuman reservoirs (37), that patients with CDI transmit at
the base CDI rate multiplied by the community transmission rate modifier, and that asymptomatically colonized
patients transmit at the base asymptomatic rate multiplied by the community transmission rate modifier. Because there are insufficient published data with which to
statistically differentiate between human transmission in
the community and nonhuman acquisition, we estimated the force of colonization directly during our model
calibration and then calculated the upper bounds for the

(29)
(35)

community transmission rate modifier and for the rate of
nonhuman acquisition.
Although age, history of antimicrobial drug use, and
concurrent conditions are predictors of diarrheal CDI,
they are not predictors of asymptomatic C. difficile colonization (38,39). Therefore, we assumed that the rate at
which symptomatic CDI developed in colonized patients
was dependent on age, antimicrobial drug use, concurrent
conditions, and hospitalization status. Transmission parameters and force of colonization were independent of
age, antimicrobial drug use or concurrent conditions (online Technical Appendix).
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Calibration

We used the Markov Chain Monte Carlo Metropolis algorithm (40) to calibrate our stochastic model and combined prior parameter densities (Table 1) with epidemiologic data, including asymptomatic prevalence and CDI
incidence in the hospital, LTCF, and community (online
Technical Appendix Table 2). This analysis yielded an
ensemble of 1,000 parameter sets that estimated the joint
posterior distribution for parameters with prior literature
estimates (Table 1) for the 5 transmission parameters and
for the base rate at which CDI developed in asymptomatically colonized persons (Table 2). Details of coding,
the stochastic model, and calibration are provided in the
online Technical Appendix.
Epidemiologic Analysis

To estimate relative infectivity of a hospitalized patient with
CDI compared with a hospitalized asymptomatically colonized patient, accounting for isolation protocols, we computed the ratio of 1) the base CDI transmission rate from a
hospitalized patient with CDI multiplied by the probability
that the patient is either not given a diagnosis or that isolation
protocols are improperly implemented to 2) the base asymptomatic transmission rate from a hospitalized, asymptomatically colonized patient. To generate a posterior distribution
for this ratio, we repeated this calculation for each of the
1,000 runs in our posterior sample. To estimate the average
risk for a person to become exposed to and colonized with C.
difficile, for each of the runs, we computed the average force
of colonization within the hospital, community, and LTCF.
To estimate an upper bound for the community
transmission rate and for nonhuman acquisition, we first

computed the daily average community force of colonization, which represents the sum of C. difficile transmission
from other persons in the community plus acquisition from
nonhuman reservoirs. By setting the nonhuman acquisition
rate to 0, we calculated an upper bound for the community transmission rate. Likewise, by setting the community
transmission rate to 0, we calculated an upper bound for
nonhuman acquisition. We repeated this step for each of
the 1,000 runs and generated posterior distributions for the
upper bounds of the community transmission rate and the
nonhuman acquisition rate.
Control Strategy Analysis

To quantify the effect of transmission control interventions
on CDI incidence, we varied each of the following factors:
CDI diagnosis rate of a hospitalized patient with CDI, effectiveness of isolation protocols for a patient given a diagnosis, overall hospital hygiene, improvements in community transmission, and improvements in LTCF transmission
across a range from 0 to double the model-fitted maximum
likelihood estimate and while sampling all other model parameters from their posterior distributions. We used linear
regression to determine the reduction for hospital-onset CDI,
community-onset CDI, and LTCF-onset CDI incidence per
1% improvement in each transmission control intervention.
To compute the effect of different classes of antimicrobial drugs on CDI incidence, we varied the antimicrobial
drug risk ratio in the hospital from 1, which is representative
of low-risk antimicrobial drugs (e.g., tetracyclines), to 20,
which is representative of high-risk antimicro- bial drugs
(e.g., clindamycin) (2). While varying the antimicrobial
drug risk ratio, we sampled all other parameters, including

Table 2. Calibrated posterior estimates of previously unknown epidemiologic parameters for infection with Clostridium difficile*
Parameter description
Posterior rate (95% CI)
Hospital force of colonization†
0.023 (0.017–0.032)
Base CDI transmission rate within hospital†
1.2 × 102 (0.65–2.1 × 102)
Base CDI transmission rate within hospital accounting for isolation/control measures†
6.0 × 103 (3.6–9.7 × 103)
Base asymptomatic transmission rate within hospital†
4.0 × 104 (2.4–5.5 × 104)
Relative transmission from patients with CDI compared with asymptomatically colonized patients,
15 (7.2–32)
accounting for isolation/control measures‡
LTCF force of colonization†
3.7 × 103 (0.96–7.7 × 103)
LTCF transmission rate, relative to hospital‡
0.13 (0.068–0.22)
LTCF transmission rate, relative to hospital, accounting for hospital CDI isolation/control measures‡
0.27 (0.13–0.51)
Community force of colonization†
1.2 × 103 (0.50–2.3 × 103)
Community transmission rate, relative to hospital‡§
5.2 × 104 (3.3–8.9 × 104)
Community transmission rate, relative to hospital, accounting for hospital CDI isolation/control
1.0 × 103 (0.62–2.0 × 103)
measures‡ §
Rate of community acquisition from nonhuman reservoirs§
1.2 × 103 (0.50–2.3 × 103)
Base rate of CDI developing in hospital†¶
2.1 × 104 (1.0–4.7 × 104)
Base rate of CDI developing in LTCF†¶
8.6 × 105 (1.1–22 × 105)
Base rate of CDI developing in community†¶
6.3 × 106 (2.9–12 × 106)
Base rate of CDI developing given concurrent conditions†¶
2.6 (0.78–6.8)
*CDI, C. difficile infection; LTCF, long-term care facility.
†Parameter rates are per day.
‡Parameter rate expresses relative risk.
§Parameter rate represents an upper bound on the risk for transmission or acquisition within the community.
¶For a detailed decomposition of the rate of development of CDI, see the online Technical Appendix (http://wwwnc.cdc.gov/EID/article/22/4/15-0455Techapp1.pdf).
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community and LTCF antimicrobial drug risk, from their
posterior distributions, thereby obtaining 95% CIs for our
estimates of the effect of antimicrobial drug class on CDI
incidence. We repeated this analysis for antimicrobial drug
risk in the community and the LTCF. We then calculated
changes in hospital-onset CDI, community-onset CDI, and
LTCF CDI incidence as hospital, community, and LTCF
risk for antimicrobial drug use were varied.
Results
Epidemiology

For within the hospital, we computed that the ratio of transmission from an isolated symptomatic patient with CDI with
transmission from an asymptomatic patient was 15 (95%
CI 7.2–32) (Table 2). This high ratio indicates that a symptomatic patient with CDI contributes more to transmission
than does an asymptomatically colonized patient, even after accounting for C. difficile protocols. Within the LTCF,
the transmission rate from a person with CDI to an uncolonized person is 27% (95% CI 13%–51%) that of the hospital, and the transmission rate from an asymptomatically
colonized person to an uncolonized person is 13% (95% CI
6.8%–22%) that of the hospital. Within the community, the
transmission rate from a person with CDI to an uncolonized
person is 0.1% (95% CI 0.062%–0.2%) that of the hospital,
and the transmission rate from an asymptomatically colonized person to an uncolonized person is 0.052% (95% CI
0.033%–0.089%) that of the hospital (Table 2).
To estimate the average risk for a person to become exposed to and be colonized with C. difficile, we computed the
force of colonization. We calculated that an uncolonized person in the hospital has a probability of 2.3% (95% CI 1.7%–
3.2%) per day of acquiring C. difficile and becoming a carrier (with or without symptoms); an uncolonized person in
the community has a probability of 0.12% (95% CI 0.050%–
0.23%) per day, and a person in an LTCF has a probability
of 0.37% (95% CI 0.096%–0.77%) per day (Table 2). These

results provide a quantitative estimate of the average risk for
C. difficile exposure to persons in each setting.
Control Strategy

To estimate the effect of transmission control interventions
on CDI incidence, we computed the percentage reduction
in hospital-onset CDI, community-onset CDI, and LTCF
CDI per percentage improvement in hospital CDI diagnosis
rate, effectiveness of isolation protocols, overall hospital
hygiene, transmission in the community, and transmission
in an LTCF (Figure 3). We found that CDI diagnosis rate,
effectiveness of isolation, overall hospital hygiene, and
transmission in the community, but not transmission in an
LTCF, affected hospital-onset CDI. In addition, community-onset CDI and LTCF CDI were not affected by hospitalbased transmission interventions.
As the relative risk for antimicrobial drug class prescribed within each of the settings was increased, the CDI
incidence likewise increased within that setting (Figure 4).
However, there was no relationship between the antimicrobial drug class prescribed within a location and CDI incidence in another location. Specifically, we estimated that for
every unit increase in antimicrobial drug risk ratio, the CDI
incidence increased by 160% (95% CI 98%–320%) in the
hospital, 33% (95% CI 13%–83%) in the LTCF, and 6.4%
(95% CI 3.9%–13%) in the community. These results indicate that the effect of antimicrobial drug risk on CDI incidence is intertwined with C. difficile transmission dynamics,
which differ between the hospital, LTCF, and community.
Discussion
Through stochastic simulation and Bayesian model calibration, we estimated C. difficile transmission rates within
and outside the healthcare setting. We also quantified the
effect on CDI incidence of control interventions that reduce
these transmission rates. We found that a person with CDI
in an LTCF transmits at a rate 27% that for a comparable
patient in the hospital, and a colonized person or a person

Figure 3. Effectiveness of Clostridium difficile infection (CDI) control parameters on incidence of infection quantified as percentage
change in hospital-onset CDI (HO-CDI), community-onset CDI (CO-CDI), and long-term care facility (LTCF)–onset CDI (LO-CDI),
quantified as percentage change in incidence per 1% change in each of 5 transmission parameters. Error bars indicate 95% CIs. LTCF,
long-term care facility.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 4, April 2016
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Figure 4. Increase in Clostridium difficile infection (CDI) incidence
from use of antimicrobial drugs for in hospital-onset (HO-CDI),
community-onset (CO-CDI), and long-term care facility–onset
(LO-CDI) illnesses classified by drug risk ratio for CDI. Clostridium
difficile infection (CDI) incidence from use of antimicrobial
drugs for low through high CDI risk. Change in CDI incidence is
measured as a multiple of the CDI incidence for an antimicrobial
drug risk ratio = 1.0. Error bars indicate 95% CIs.

with CDI in the community transmits C. difficile to others
at a rate <0.1% that of a comparable patient in the hospital.
Despite the lower community transmission rate, we found
that because of the much larger pool of colonized persons
in the community, interventions that reduce community
transmission hold substantial potential to reduce hospitalonset CDI by reducing the number of patients entering the
hospital with asymptomatic colonization. Moreover, our
results show that in the hospital, symptomatic CDI patients
under isolation and infection control measures nonetheless transmit CDI to uncolonized patients at a rate that is
15 times greater than that of asymptomatic carriers. This
higher rate of transmission indicates that toxin-targeting
treatments (such as vaccines); nontoxigenic C. difficile;
and monoclonal antibodies, which might protect against
symptomatic CDI but not against asymptomatic colonization, could be effective tools for reducing not only primary
CDI cases but also for further transmission (9).
Our epidemiologic results underscore the need for
incorporating and understanding transmission dynamics
within and outside healthcare settings when evaluating C.
difficile control strategies. Although C. difficile transmission rates are lower among asymptomatically colonized
persons, residents of LTCFs, and persons in the community
than in hospitalized patients with symptomatic CDI, overall CDI incidence is driven by several factors: transmission,
antimicrobial drug use, and underlying population health.
We found that, per unit increase in relative antimicrobial
drug risk, CDI incidence increases by a factor of 160% in
the hospital and 33% in the LTCF but only by a factor of
6.4% in the community. This finding is a consequence of
amplification by concentration.
When we compared patients in the hospital and LTCF
with persons in the community, we found that patients are
614

closer to each other, are more frequently receiving antimicrobial drugs, and tend to have poorer overall health or may
be immunocompromised. These attributes combine to yield
a greater risk for infection and transmission. This finding
of amplification-by-concentration has major implications
for antimicrobial drug risk management: those antimicrobial drugs strongly associated with CDI, such as clindamycin, cephalosporins, and fluoroquinolones (2), will have a
more detrimental effect on overall CDI incidence in a hightransmission setting, such as a hospital, than they will in
a moderate-transmission setting, such as an LTCF, or in a
low-transmission setting, such as the community.
We found no major effect of hospital-based transmission interventions on LTCF-onset CDI or of LTCF-based
transmission interventions on hospital-onset CDI. This
finding suggests that although C. difficile can be introduced
by a patient who acquired the bacteria in the hospital, CDI
outbreaks in LTCFs are driven primarily from within and
are best mitigated by targeted transmission interventions
within the facility. Likewise, any interventions to reduce
transmission within an LTCF will have limited effect on
hospital-onset CDI because LTCF transmission interventions will not influence continued introduction of C. difficile to the hospital from the community.
The control strategies we evaluated (Figure 3) are representative of a broad range of interventions. For example,
an improvement in hospital isolation effectiveness could
be achieved through enhanced hospital staff adherence to
precautions, or alternatively through an increased capacity
to keep a patient with CDI in isolation for the duration of
the disease. An improvement in the LTCF transmission rate
could be achieved through an improvement to LTCF staff
hygiene and cleanliness, through an increased availability
of private facilities for residents, or through the isolation of
LTCF residents with CDI.
Although there are few data with which to differentiate
the sources of community-associated C. difficile, we were
able to use a community C. difficile colonization study (37)
to calibrate our model. From our calibrated model, we estimated the overall community force of colonization and
calculated an upper bound for the community transmission
rate. Future studies of similar design but with greater statistical power than the study used for our calibration (37),
which survey healthy, nonhospitalized adults for asymptomatic C. difficile carriage while differentiating community risk factors, would provide the necessary data with
which our model could directly quantify transmission from
human sources and acquisition from nonhuman reservoirs.
Our analyses demonstrated that C. difficile transmission
among healthcare settings and the community is interconnected, and there are comparable effects of communitybased transmission and hospital-based transmission on hospital-onset CDI. We found that the effect of antimicrobial
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drug use on CDI incidence is modulated by transmission dynamics, with specific antimicrobial drugs exacerbating incidence, and doing so to a greater degree in high-transmission
settings than in low-transmission settings. These results underscore the need for empirical quantification of communityassociated transmission and the need of understanding transmission dynamics in all settings when evaluating C. difficile
interventions and control strategies.
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